Hydroxychloroquine-Induced Creatine Kinase Elevation

Hidroksiklorokin Kaynaklı Kreatin Kinaz Yükselmesi

Sinem BAYRAKÇI1(ID), Nursel SÜRMELIOĞLU2(ID), Ezgi ÖZYILMAZ3(ID)

1 Intensive Care Unit, Faculty of Medicine, Cukurova University, Adana, Turkey
2 Department of Clinical Pharmacy, Faculty of Pharmacy, Cukurova University, Adana, Turkey
3 Department of Chest Diseases, Faculty of Medicine, Cukurova University, Adana, Turkey

ABSTRACT

Long-term administration of hydroxychloroquine and chloroquine leads to deposition in the tissues including muscles, nerves and retina. Here, we report a case of hydroxychloroquine induced creatine kinase elevation after loading dose. An 80-year-old man with comorbidities, presented with a dry cough, high fever, diarrhea and general condition disorder ongoing for the last 3 days. The patient was admitted to the intensive care unit. The treatment was commenced with hydroxychloroquine. On the first day of treatment, the loading dose of hydroxychloroquine was started as 400 mg q12h, and treatment was continued as 200 mg q12h from the 3rd dose. After the hydroxychloroquine loading dose, the patient’s creatine kinase level increased, and after drug cessation, the level decreased. Hydroxychloroquine-induced creatine kinase elevated may be on not only long-term use but also acute period. Clinicians should have a high suspicion for hydroxychloroquine toxicity in patients with risk factors.

Key Words: Hydroxychloroquine; Toxicity; Creatine kinase; Adverse effect

CASE REPORT/OLGU SUNUMU

Received/Geliş Tarihi: 17/08/2020 - Accepted/Kabul Ediliş Tarihi: 30/10/2020

© Copyright 2020 by Flora. Available online at www.floradergisi.org.
Available Online Date: 31.12.2020
INTRODUCTION

Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial drugs that are also used in the treatment of various rheumatic diseases\[1,2\]. With the declaration on March 11th, 2020, by the World Health Organization that coronavirus disease 2019 (COVID-19) is a pandemic, CQ and HCQ have been sporadically used in treating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection due to their proposed immunomodulatory effect and also proposed usefulness in controlling the cytokine storm\[3\].

HCQ is safer and better-tolerated than CQ, and the use of HCQ has been increased\[4\]. HCQs most common side effects include gastrointestinal symptoms, pruritus and dermatological changes that can occur in up to 10% of the patients. The most severe side effects have low incidence\[5,6\]. HCQ is known to have significant lysosomal affinity. Long-term administration leads to deposition in tissues including the muscles, nerves and retina. They include neumyopathy, cardiotoxicity and irreversible retinopathy\[5,7\]. Neumyotoxicity is a rare side effect with a reported prevalence up to 6.7%. It is characterized by proximal muscle weakness, generally normal creatine kinase (CK) levels, and characteristic ultrastructural changes on muscle biopsy of curvilinear body formation\[2,8,9\].

Here, we report a case of hydroxychloroquine induced CK elevation after loading dose.

CASE

An 80-year-old man with dementia, hypertension, and previous cerebrovascular accident presented with a dry cough, high fever, diarrhea and general condition disorder ongoing for the last 3 days to the emergency department. He was tachycardic, normotensive, Glasgow Coma Scale is 14, oxygen saturation was 100% with a nasal cannula of 4-liter per minute oxygen support. The patient’s PCR (polymerase chain reaction) test performed twice was negative, but since thorax computed tomography results were compatible with COVID-19, he was followed as a possible case. The patient was admitted to the COVID intensive care unit with hypernatremia, prerenal acute renal failure, and bilateral ground-glass areas in the lung.

Treatment was commenced with HCQ, 0.45% NaCl, and 5% Dextrose solution, Vitamin C, Vitamin B complex, Aspirin (100 mg q24h), Ranitidine (50 mg q24h). On the first day of treatment, the loading dose of HCQ was started...
as 400 mg q12h, and treatment was continued as 200 mg q12h from the 3rd dose. At the initial laboratory findings, serum CK of 126 U/L (normal range, 26-140 U/L), creatinine kinase MB (CK-MB) of 5 ng/mL (normal range, 0.0-4.5 ng/mL) and creatinine (Cr) of 0.9 (normal range, 0.5-0.8 mg/dL). After the 2nd and 4th dose of HCQ, CK was increased to 233 U/L, CK-MB: 5 ng/mL; and CK: 3715 U/L, CK-MB: 37 ng/mL, respectively. HCQ treatment was stopped after the 6th dose. CK levels decreased 72 hours after cessation (Table 1). During the treatment, liver functions were normal and kidney functions returned to normal. Drug-related adverse drug reaction (ADR) was evaluated through the Naranjo scale 10, and the score was calculated as 3 (Table 2).

HCQ is cationic, amphiphilic compounds with long half-lives of 3.5-12 days. It has a significant lysosomal affinity[1]. HCQ induced myopathy is thought to be due to the accumulation of hydroxychloroquine in lysosomes[2]. In myopathy induced by HCQ, although muscle enzymes are generally stated to be normal[2], CK and CK-MB increased rapidly in this case.

Risk factors for myotoxicity are poorly understood but may include the Caucasian race, renal failure, older age, female sex and concomitant use of other myotoxic drugs[1,4]. In this case, patient had renal dysfunction and older age.

| Days | Cr (mg/dL) | CK (U/L) | CK-MB (ng/mL) |
|------|------------|----------|---------------|
| 1    | 3.8        | 126      | 1.9           |
| 2    | 3.23       | 233      | 5             |
| 3    | 2.04       | 3715     | 37            |
| 7    | 1.34       | 1750     | 23.2          |
| 13   | 0.72       | 166      |               |

*Cr: Creatinin, CK: Creatine Kinase, CK-MB: Creatine kinase-MB.

| Yes | No | Do not know | Score |
|-----|----|-------------|-------|
| 1.  | +1 | 0           | +1    |
| 2.  | +2 | -1          | 0     |
| 3.  | +1 | 0           | 0     |
| 4.  | +2 | -1          | 0     |
| 5.  | -1 | +2          | 0     |
| 6.  | -1 | +1          | 0     |
| 7.  | +1 | 0           | 0     |
| 8.  | +1 | 0           | 0     |
| 9.  | +1 | 0           | 0     |
| 10. | +1 | 0           | 0     |

Total Score* 3

*The adverse drug reaction was assigned to a probability category from the total score as follows: definite ≥ 9, probable 5 to 8, possible 1 to 4, doubtful ≤ 0.
Another risk factor is reported to be the duration of treatment. In the literature, myopathy and/or muscle enzyme elevation has generally been reported after long-term HCQ treatment[1,2,4]. But in this case, CK and CK-MB increased after the loading dose. Interestingly, although the duration of treatment may lead to progressive and additive changes, it is not clear if the occurrence of HCQ-induced myotoxicity is dose-dependent[4].

Naranjo algorithm was used for objective evaluation of CK elevation due to HCQ. According to this algorithm, its total score was 3 points. This score shows that the side effect was possibly (1-4) caused by drugs (Table 2). In addition, there are no other drugs known to be myotoxic in the treatment, but it is reported that COVID-19 can cause CK elevation[11].

HCQ-induced muscle enzyme elevation may be on not only long-term use but also acute period. If it is not noticed early, it can have serious consequences. Clinicians should have a high suspicion for HCQ toxicity in patients with risk factors.

CONFLICT of INTEREST

The authors have disclosed that they do not have any potential conflicts of interest.

AUTHORSHIP CONTRIBUTIONS

Concept/Design: All of authors
Analysis/Interpretation: SB, NS
Data Acquisition: All of authors
Writting: SB, NS
Final Approval: All of authors

REFERENCES

1. Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008;38(3):1206-10.
2. Takizawa N, Fujita Y. A rare but reversible cause of myopathy: hydroxychloroquine induced myopathy. Am J Med 1987;82(3):447.
3. Yıldırım F. Chloroquine and hydroxychloroquine in treatment of COVID-19 disease. J Crit Intensive Care 2020;11(Suppl.1):23-26.
4. Kwon JB, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney R. Hydroxychloroquine-induced myopathy. JCR-J Clin Rheumatol 2010;16(1):28-31.
5. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J 2020;0:1-6.
6. Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 2018;30:249-55.
7. Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61.
8. Khosa S, Khanlou N, Khosa GS, Mishra SK. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 2018;38(6):646-52.
9. Siddiqui AK, Huberfeld SJ, Weidenheim KM, Einberg KR, Efferen LS. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 2007;131(2):588-90.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz J, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
11. Chan KH, Farouji I, Harnoud AA, Slim J. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med 2020;38(7):1548.e1-1548.e3.

Address for Correspondence/Yazışma Adresi
Asistan Dr. Nursel SÜRMELİOĞLU
Çukurova Üniversitesi Eczacılık Fakültesi
Klinik Eczacılık Anabilim Dalı
Adana-Türkiye
E-mail: nurselisci@gmail.com